18,970 views
http://www.medicinaeinformazione.com/ / medicinaeinformazione Rheumatoid arthritis, a chronic inflammatory disease of autoimmune origin that affects, especially in the initial phase, the small joints of the hands, has benefited in recent years from innovative therapies, biological drugs that allow many patients to control the disease over time. But not all patients have a good response to the latest generation monoclonal antibodies and to avoid useless therapies that can also cause side effects in patients who would not benefit from them anyway, it is now possible to study the metabolomic profile of a patient (with a procedure that allows you to trace the profile of what happens from a metabolic point of view in a subject in particular circumstances, in basal situations, following environmental exposure and following the intake of certain drugs) so as to administer biological therapies only to those who will really benefit from them. And to talk about the study that allows this information, published in Plos One we spoke with one of the authors, Prof. Guido Valesini, Director of the Department of Internal Medicine and Medical Specialties at the Policlinico Umberto I in Rome and Full Professor of Rheumatology at La Sapienza University of Rome who explained to us how today the diagnosis of rheumatoid arthritis makes use of sophisticated investigation tools such as joint ultrasound and particular blood tests so as to be able to arrive at an early diagnosis that allows to start a personalized treatment path - also thanks to the study of the personal metabolic response precisely - that keeps the evolution of the disease under control. But in addition to drugs, lifestyle is also important and it is now known with certainty that cigarette smoking is an aggravating factor of inflammation and therefore should absolutely be avoided, while a careful diet (and with a low protein intake) and constant physical activity - which also prevents obesity, another negative factor - can help improve the quality of life.